Cannabis Law Report

NOVEMBER 5, 2021

The licensing process has been in turmoil since early 2020, when state officials delayed it, blaming the COVID-19 pandemic. Attorney General Kwame Raoul’s office had argued in court papers that combining the cases would avoid potentially conflicting rulings.

Recreational 98

Recreational Dispensary Retail Law 98

Cannabis Law Report

NOVEMBER 26, 2021

Can-Fite Ends Phase II COVID-19 Trial to Focus on Core Indications – In 2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, Can-Fite initiated a Phase II COVID-19 study of its lead drug candidate, Piclidenoson, with patient enrollment in Israel and Europe.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

NOVEMBER 17, 2021

COVID-19 considerations: Employees are required to provide proof of vaccination. Benefits: 401(k). 401(k) matching. Dental insurance. Flexible schedule. Health insurance. Paid time off. Parental leave. Vision insurance. Schedule: Monday to Friday. Supplemental Pay: Bonus pay. Experience: Corporate Legal: 2 years (Preferred).

Packaging 52

Packaging Business Legalization Cannabis 52

Cannabis Law Report

NOVEMBER 9, 2021

Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the duration of the COVID-19 pandemic and the pace of recovery following the pandemic, any additional resurgence, or COVID-19 variants; the short and longer-term effects of the COVID-19 pandemic, including the demand for travel, transient (..)

Wellness and Beauty 52

Wellness and Beauty Business Collective Retail 52

Cannabis Law Report

NOVEMBER 17, 2021

Canadian marijuana industry employment tumbled as producers drew federal COVID-19 cash, analysis shows. and their infographic certainly tells a story. This when all cannabis companies in North America were using as their byline… t he pandemic brought cannabis to the mainstream.

Business 52

Business Programs Cannabis Marijuana 52

Cannabis Law Report

NOVEMBER 29, 2021

New Jersey’s overdose and COVID-19 crises created a “pandemic within a pandemic,” and residents have borne the consequences of years of underinvestment in New Jersey’s public health infrastructure. The Movement for Black Lives, arguably the largest social movement in U.S.

Policy 52

Policy Decriminalization Treatment History 52

Cannabis Law Report

NOVEMBER 22, 2021

Emyria was listed on the ASX last year, just before Australia was plunged into the global COVID-19 pandemic, and has been progressing with trials of a synthetic cannabinoid targeting mental health which it hopes to have registered domestically and in the American market.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

NOVEMBER 15, 2021

As a result of the COVID-19 pandemic, nucleic acid therapies have also moved to the forefront of biotherapeutic science with the successful deployment of mRNA vaccines against the virus. Applied DNA has also established a COVID-19 diagnostic and testing offering that is grounded in the Company’s deep expertise in DNA.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

NOVEMBER 24, 2021

The adoption of the QuickStrip™ as a viable drug delivery method has confirmed and validated the technology as an effective needle free COVID-19 vaccine candidate. About Rapid Dose Therapeutics Corp. Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation.

Research and Development 52

Research and Development Events Access Pharmaceutical 52

Cannabis Law Report

NOVEMBER 18, 2021

What has been the impact of COVID-19 on the global high temperature insulation materials market? Impact of COVID-19. Key Questions Answered in This Report: How has the global high temperature insulation materials market performed so far and how will it perform in the coming years? What are the key regional markets?

Environment 52

Environment Research and Development Topical Hemp 52

Cannabis Law Report

NOVEMBER 1, 2021

(NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

Cannabis Law Report

NOVEMBER 22, 2021

The minister also acknowledged the COVID -19 situation has affected the Thai economy, and to alleviate the situation, the economic reform and new opportunities required. According to the study, cannabis can treat various diseases such as cancer, epilepsy, multiple sclerosis with muscle pain, and neuralgia.

Research and Development 52

Research and Development Epilepsy Cannabis Food 52

Cannabis Law Report

NOVEMBER 23, 2021

MYMD-1 is also showing promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 12, 2021

Finally, BreathTech is expecting to begin human trials of its BreathTest-1000™ with the Cleveland Clinic in the first calendar quarter, taking us one step closer to entering the battle against COVID-19. We continue to garner interest from the cargo security marketplace as it continues to expand compared to pre-COVID-19 levels.

Research and Development 52

Research and Development Data Hemp Events 52

Canna Law Blog

NOVEMBER 7, 2021

With COVID-19, taxes, school issues, etc., I’m not trying to suggest that legalization is impossible. There are still a lot of folks who think that this can happen even without an act of Congress. But possibilities and likelihoods are two very different stories.

Legalization 87

Legalization Decriminalization Legislation Cannabis 87

Cannabis Law Report

NOVEMBER 16, 2021

MYMD-1 is also showing promise as a potential treatment for post-COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

NOVEMBER 9, 2021

For many, the effects of the COVID-19 pandemic were devastating—socially, professionally, physically, emotionally, and mentally. For a farmer in the Central Highlands province of Dak Lak, Vietnam, a serious change was needed in order to survive the pandemic.

Cultivation 98

Cultivation Seed-To-Sale Cannabis Agriculture 98

Cannabis Law Report

NOVEMBER 18, 2021

Impact of health epidemics and pandemics, including the COVID-19 pandemic, and the risk of the resulting negative economic impact and related governmental actions. Higher costs, lower quality, or unavailability of energy, water, raw materials, product ingredients, or labor.

Supply Chain 52

Supply Chain Business Policy Consumption 52

Cannabis Law Report

NOVEMBER 10, 2021

COVID-19 Statement. In March 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. We did not experience in 2020, and to date have not experienced in 2021, any material changes to our operations from COVID-19.

Business 52

Business Media Events Environment 52

Cannabis Law Report

NOVEMBER 18, 2021

Analysis of COVID-19 impact on the Eco-friendly Labels Market. Eco-friendly Labels Market Regional Highlights. Global Eco-friendly Labels Market Overview. Introduction. Market Dynamics. Restraints. Opportunities. Porter’s Five Forces Analysis. Growth Matrix Analysis. Growth Matrix Analysis by Material.

Hemp 52

Hemp Packaging Pharmaceutical Collective 52

Cannabis Law Report

NOVEMBER 18, 2021

Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements.

Seed-To-Sale 52

Seed-To-Sale Data Research and Development Packaging 52

Cannabis Law Report

NOVEMBER 9, 2021

Applied DNA has also established a COVID-19 diagnostic and testing offering that is grounded in the Company’s deep expertise in DNA. About Applied DNA Sciences. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

NOVEMBER 4, 2021

COVID-19 Impact Analysis. Increasing healthcare costs. Restraints and Challenges. Volatility in prices. Porter’s Five Forces Analysis. PESTLE Analysis. Superfoods Market Industry trends. Global Superfoods Market, by Type. Key Findings. Introduction. Global Superfoods Market, by Type, 2016 – 2028 (USD Billion).

Research and Development 52

Research and Development Food Topical Hemp 52

Cannabis Law Report

NOVEMBER 1, 2021

Damage local small businesses and communities, still reeling from the impact of COVID-19. Cost New York state millions in tax revenue. Hurt minority-owned and women-owned businesses while creating a negative cultural impact on commerce in the state. Harm veterans who use Delta-8 THC to help PTSD.

THC 52

THC CBD Pets Business 52

Veriheal

NOVEMBER 29, 2021

’s gifting culture continued to thrive—and it saw a whole new level of popularity once the COVID-19 pandemic hit in early 2020. 19, the city held a public hearing that allowed stakeholders to give their two cents on how recreational legalization should be handled. Since Initiative 71 went into effect, D.C.

Recreational 52

Recreational Business Legislation Cannabis 52

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. OXFORD, Ohio and COCONUT CREEK, Fla., “These patent filings are critical components of PsyBio’s corporate development strategy. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Canna Law Blog

NOVEMBER 6, 2021

The COVID-19 pandemic made things worse. Amid a worsening mental health crisis, the dam preventing scientific progress must be broken. For two decades, U.S. suicide rates have steadily increased, and drug overdose rates have skyrocketed. Since 2019, anxiety rates tripled, and overdose rates surged.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

NOVEMBER 18, 2021

In addition, MCOA’s hempSMART business improved gross profits due to new pricing and promotions associated with sales restructuring and new sales strategies, along with the effects of the COVID-19 pandemic subsiding during the three months ended September 30, 2021. As a result, the combined gross margins were 14.4%

Marijuana 52

Marijuana Cultivation History CBD 52

Cannabis Law Report

NOVEMBER 17, 2021

The death sentence comes within weeks as another drug trafficker, a 33-year old Malaysian Indian , awaits the outcome of his last ditch appeal to be spare the gallows while his hanging, originally scheduled for November 10, has been stayed due to COVID-19 infection.

Collective 52

Collective Media Law 52

The Joint Blog

NOVEMBER 15, 2021

This is in part due to the COVID-19 pandemic and its ensuing lockdowns. Here are some of the benefits that they believe one can derive from microdosing certain drugs: Mental Health Issues. Mental health issues in America are higher than they have ever been before.

Microdosing 49

Microdosing Clinical Trials Pharmaceutical Cannabinoids 49

Cannabis Law Report

NOVEMBER 17, 2021

There was an enormous surge in the market, particularly in the dog segment, thanks to an influx in pet owners since the onset of Covid-19. The global CBD pet market was valued at $125m in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 58.9%

Pets 52

Pets CBD Research and Development Hemp 52

Cannabis Law Report

NOVEMBER 15, 2021

managing our growth; restrictive covenants under our credit facilities; natural catastrophes; the ongoing and developing COVID-19 pandemic; and tax risks.?. These risks and uncertainties include, among other things, the factors contained in the Company ‘s filings with securities regulators, including this press release.?In

Agriculture 52

Agriculture Events Retail Environment 52

Cannabis Law Report

NOVEMBER 22, 2021

A variety of factors, including known and unknown risks, many of which are beyond the Company’s control, could cause actual results to differ materially from the forward-looking information and statements in this press release including, without limitation: ability to effectively deal with the restrictions, limitations and health issues presented by (..)

Retail 52

Retail Conditions Media Business 52

Cannabis Law Report

NOVEMBER 16, 2021

Meadow started building these features as delivery became critical in the early days of the COVID-19 pandemic. So now dispensaries can push out into those territories by putting a car out there.”. Then, as the pandemic dragged into 2021, the company started building out in earnest.

Dispensary 52

Dispensary Retail Cannabis Compliance 52

Cannabis Law Report

NOVEMBER 1, 2021

While employers in the US transport industry are acutely aware of the effects COVID-19 has imposed over the last 18 months, another phenomenon has been making itself known: the ever-increasing tally of states and localities across the country legalising cannabis for medicinal and recreational purposes. 01 November 2021. by Keya C.

Recreational 52

Recreational Safety Cannabis Law 52

Cannabis Law Report

NOVEMBER 10, 2021

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company’s operations, clinical development plans and timelines, which may (..)

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

NOVEMBER 4, 2021

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements.

Topical 52

Topical CBD Retail Research and Development 52